Myeloma Today: Fall 2023
In the Fall 2023 edition, IMF Chief Medical Officer Dr. Joseph Mikhael highlights the approval of two new myeloma drugs. Those drugs, ELREXFIO™ and TALVEY™, are both bispecific monoclonal antibodies, and they offer innovative treatment options for patients with relapsed or refractory myeloma. The edition also features the IMF's M-Power health equity initiative, with a focus on the achievements of Medical Student Scholars and successful educational events held in New York. The IMF’s Nurse Leadership Board's 19th annual meeting is also covered, focusing on collaborations and programs supporting myeloma nurses and empowering patients. The issue includes an article on the crucial role of care partners in helping loved ones live well with myeloma. Lastly, the IMF's 2023 Blood Cancer Awareness Month campaign is recapped, exploring the important question, "Do You Know Myeloma?”, and more.